Keytruda generated $31.6bn last year. Cipla and Qilu are positioning a biosimilar for the U.S. market
Cipla’s Invagen has licensed U.S. rights to Qilu’s investigational pembrolizumab biosimilar QL2107, setting up a future challenge to Merck’s blockbuster Keytruda franchise.